Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Betaferon

Novartis building

Novartis’ Zortress cleared by FDA for liver transplants

Adds to kidney transplant indication in the US

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

EU flag

Pharma backs new European drug discovery platform

Supporters for the European Lead Factory include Bayer AstraZeneca, Merck KGaA and Sanofi

- PMLiVE

Biogen gains full rights to Tysabri in $3.25bn deal with Elan

Ends decade-long partnership for MS drug

- PMLiVE

Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna

- PMLiVE

EC to investigate Novartis and J&J in antitrust probe

Claims companies agreed to delay entry of generic painkiller

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

Bayer’s Diane 35 faces ban in France

Follows investigation into blood clot-related deaths

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

EMA starts contraceptive safety probe

Follows French investigation into Bayer’s Diane 35

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links